Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-lge monoclonal antibody

Journal of Pharmaceutical Sciences

Volumn 87, Issue 11, 1998, Pages 1406-1411

  Costantino, Henry R ^a   Andya, James D ^a   Nguyen, Phuong Anh ^a   Dasovich, Nancy ^a   Sweeney, Theresa D ^a   Shire, Steven J ^a   Hsu, Chung C ^a   Maa, Yuh Fun ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL; PROTEIN; RECOMBINANT HUMANIZED ANTI IGE MONOCLONAL ANTIBODY; SODIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG;

AEROSOL; CONFERENCE PAPER; CRYSTALLIZATION; DRUG FORMULATION; DRUG STABILITY; PARTICLE SIZE; POWDER; PROTEIN STABILITY; X RAY POWDER DIFFRACTION;

ANTIBODIES, ANTI-IDIOTYPIC; DRUG STABILITY; EXCIPIENTS; HUMANS; MANNITOL; PROTEINS;

EID: 0031793406     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9800679     Document Type: Article

References (22)

1. Broadhead, J.; Edmon Rouan, S. K.; Hau, L; Rhodes, C. T. The effect of process and formulation variables on the properties of spray-dried /3-galactosidase. J. Pharm. Pharmacol. 1994, 46, 458-467.
2. Mumenthaler, M.; Hsu, C. C.; Pearlman, R. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res. 1994, 11, 12-20.
3. Chan, H.-K; Clark, A.; Gonda, I.; Mumenthaler, M.; Hsu, C. C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 1997, 14, 431-437.
4. Maa, Y.-F.; Costantino, H. R.; Nguyen, P.-A.; Hsu, C. C. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm. Dev. Technol. 1997, 2, 213-223.
5. Costantino, H. R.; Andya, J. D.; Shire, S. J.; Hsu, C. C. Fourier transform infrared spectroscopic analysis of the secondary structure of recombinant humanized immunoglobulin G. Pharm. Sei. 1997, 3, 121-128.
6. Maa, Y.-F.; Nguyen, P.-A.; Andya, J. D.; Dasovich, N.; Sweeney, T. D.; Shire, S. J.; Hsu, C. C. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm. Res. 1998, 15, 768-775.
7. Maa, Y.-F.; Nguyen, P.-A.; Hsu, S. W. Spray drying of airliquid interface sensitive recombinant human growth hormone. J. Pharm. Sei. 1998, 87, 152-159.
8. Heyder, J.; Gebhart, J.; Rudolf, G.; Schiller, C. F.; Stahlhofen, W. Deposition of particles in the human respiratory tract in the size range of 0.005-15 //m. J. Aerosol Sei. 1986,17, 811825.
9. Hageman, M. J. Water sorption and solid-state stability of proteins. In Stability of Protein Pharmaceuticals. Part A. Chemical and Physical Pathways of Protein Degradation; Ahern, T. J., Manning, M. C., Eds.; Plenum Press: New York, 1992; pp 273-309.
10. Costantino, H. R.; Langer, R.; Klibanov, A. M. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J. Pharm. Sei. 1994, 83, 1662-1669.
11. The fraction of aerosol with a suitable size for aerosol delivery has been referred to in the past as "respirable fraction," and more recently it has been agreed to use "fine particle fraction" (International Society for Aerosols in Medicine Focused Symposium: Towards Meaningful Laboratory Tests for Evaluation of Pharmaceutical Aerosols, Puerto Rico, Jan 29-31, 1997). It is important to note that the range of sizes used to define the fine particle fraction depends on the device used for measuring the size of the aerosol particles, e.g., the size cutoff of the various stages of the impactor or liquid impinger used.
12. Clark, A. R.; Dasovich, N.; Gonda, L; Chan, H.-K. The balance between biochemical and physical stability for inhalation protein powders. rhDNase as an example. In Respiratory Drug Delivery V; Dalby, R. N., Byron, P. R., Farr, S. J., Eds.; Interpharm Press: Buffalo Grove, IL, 1996; pp 167-174.
13. Andya, J. D.; Nguyen, P.-A.; Maa, Y.-F.; Dasovich, T. D.; Sweeney, T. D.; Hsu, C. C.; Shire, S. J. The effect of formulation excipients and relative humidity on protein stability following storage and aerosol performance of spraydried powders of the rhuMAbE25 monoclonal antibody. Pharm. Res. 1997, 14, S-217.
14. Pikal, M. J.; Dellerman, K. M.; Roy, M. L.; Riggin, R. M. The effect of formulation variables on the stability of freeze-dried human growth hormone. Pharm Res. 1991, 8, 427-436.
15. Izutsu, K; Yoshioka, S.; Terao, T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharm. Res. 1993, 10, 1232-1237.
16. Izutsu, K.; Yoshioka, S.; Terao, T. Effect of mannitol crystalunity on the stabilization of enzymes during freeze-drying. Chem. Pharm. Bull. 1994, 42, 5-8.
17. Carpenter, J. F.; Pikal, M. J.; Chang, B. S.; Randolph, T. W. Rational design of stable lyophilized formulations. Some practical advice. Pharm. Res. 1997, 14, 969-975.
18. Gray, R.; Stern, A.; Bewley, T. A.; Voelker, P.; McRorie, D.; Liu, J.; Shire, S. J. Determination of protein concentration by improved optical methods. Pharm. Res. 1994, 11, S76.
19. Young, J. F. Humidity control in the laboratory using salt solutions-A review. J. Appl. Chem. 1967, 17, 241-245.
20. Phillips, E. M.; Carvajal, M. T.; Munroe, M. M. Characterizing variable amorphous content in powders for inhalation. In Respiratory Drug Delivery V; Dalby, R. N., Byron, P. R., Farr, S. J., Eds.; Interpharm Press: Buffalo Grove, IL, 1996pp 253-261.
21. Herman, B. D.; Sinclair, B. D.; Milton, N.; Nail, S. L. The effect of bulking agent on the solid-state stability of freezedried methylprednisolone sodium succinate. Pharm. Res 1994, 10, 1467-1473.
22. Hancock, B. C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sei. 1997, 86, 1-12.